oxybutynin has been researched along with Arthritis, Degenerative in 10 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Efficacy and tolerability of buprenorphine patches was demonstrated in chronic pain patients, regardless of age, supporting the conclusion that no age-related dose adjustment of transdermal buprenorphine is needed." | 7.80 | Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. ( Augustini, BG; Berggren, AC; Karlsson, J; Söderström, A, 2014) |
| " The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46." | 6.82 | The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. ( Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016) |
| "Adult patients with pain from osteoarthritis receiving a stable dosage of HCD/APAP (i." | 6.77 | A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain. ( Landau, CJ; McCarberg, BH; Munera, C; Ripa, SR; Wen, W, 2012) |
| "Efficacy and tolerability of buprenorphine patches was demonstrated in chronic pain patients, regardless of age, supporting the conclusion that no age-related dose adjustment of transdermal buprenorphine is needed." | 3.80 | Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. ( Augustini, BG; Berggren, AC; Karlsson, J; Söderström, A, 2014) |
| " The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46." | 2.82 | The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. ( Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016) |
| "Adult patients with pain from osteoarthritis receiving a stable dosage of HCD/APAP (i." | 2.77 | A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain. ( Landau, CJ; McCarberg, BH; Munera, C; Ripa, SR; Wen, W, 2012) |
| " The primary outcomes were pain relief for RCTs and risk of adverse effects (AEs) for observational studies." | 2.58 | Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. ( Doherty, M; Lei, G; Li, J; Li, X; Long, H; Persson, MSM; Sarmanova, A; Wang, Y; Wei, J; Xie, D; Zeng, C; Zhang, W, 2018) |
| "This syndrome is usually related to anatomic variants (involving the bone structures, fibrous bands, or muscles and tendons)." | 1.38 | Supraclavicular nerve entrapment syndrome. ( Bruyère, PJ; Courtois, AC; Crielaard, JM; Douchamps, F, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Härkänen, L | 1 |
| Hakomäki, H | 1 |
| Huopio, J | 1 |
| Kokki, H | 1 |
| Korhonen, S | 1 |
| Lehtonen, M | 1 |
| Sjövall, S | 1 |
| Kokki, M | 1 |
| Zeng, C | 1 |
| Wei, J | 1 |
| Persson, MSM | 1 |
| Sarmanova, A | 1 |
| Doherty, M | 1 |
| Xie, D | 1 |
| Wang, Y | 1 |
| Li, X | 1 |
| Li, J | 1 |
| Long, H | 1 |
| Lei, G | 1 |
| Zhang, W | 1 |
| Feragalli, B | 1 |
| Dugall, M | 1 |
| Luzzi, R | 1 |
| Ledda, A | 1 |
| Hosoi, M | 1 |
| Belcaro, G | 1 |
| Cesarone, MR | 1 |
| Ban, T | 1 |
| Hirose, H | 1 |
| Teraura, H | 1 |
| Kotani, K | 1 |
| Gotoh, T | 1 |
| Therkleson, T | 1 |
| Karlsson, J | 1 |
| Söderström, A | 1 |
| Augustini, BG | 1 |
| Berggren, AC | 1 |
| Yataba, I | 1 |
| Otsuka, N | 1 |
| Matsushita, I | 1 |
| Matsumoto, H | 1 |
| Hoshino, Y | 1 |
| Argoff, CE | 1 |
| Douchamps, F | 1 |
| Courtois, AC | 1 |
| Bruyère, PJ | 1 |
| Crielaard, JM | 1 |
| Ripa, SR | 1 |
| McCarberg, BH | 1 |
| Munera, C | 1 |
| Wen, W | 1 |
| Landau, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01276431] | Phase 4 | 102 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Randomized, Double-Blind Study Evaluating the Dose Conversion From Vicodin® to Buprenorphine Transdermal System (BTDS) in Subjects With Osteoarthritis (OA) Pain[NCT00312572] | Phase 3 | 204 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The indicator variable was 1 = completion, and 0 = noncompletion. For the primary efficacy analysis, the percentage of subjects who completed the double-blind phase was computed with its 95% confidence interval (CI) for each treatment regimen (starting dose of BTDS 10 or BTDS 20) across and within baseline Vicodin® stratum (15 to 22.5mg/day vs >22.5 to 30 mg/day as determined by the daily average hydrocodone dose during the run-in period). (NCT00312572)
Timeframe: 14 days
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| 15 - 22.5 mg HCD (Stratum 1) | more than 22.5 - 30 mg HCD (Stratum 2) | Overall | |
| Combined Total | 85 | 82 | 84 |
| Double-blind BTDS 10/20 | 88 | 85 | 87 |
| Double-blind BTDS 20 | 83 | 79 | 82 |
2 reviews available for oxybutynin and Arthritis, Degenerative
| Article | Year |
|---|---|
Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Humans; Network M | 2018 |
Recent developments in the treatment of osteoarthritis with NSAIDs.
Topics: Administration, Oral; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Humans; Osteoarthritis; S | 2011 |
2 trials available for oxybutynin and Arthritis, Degenerative
| Article | Year |
|---|---|
The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Contact; Female; | 2016 |
A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain.
Topics: Acetaminophen; Administration, Cutaneous; Administration, Oral; Aged; Analgesics, Opioid; Anti-Infla | 2012 |
6 other studies available for oxybutynin and Arthritis, Degenerative
| Article | Year |
|---|---|
Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Humans; Osteoarthritis; Transdermal Pa | 2023 |
Pycnogenol®: supplementary management of symptomatic osteoarthritis with a patch. An observational registry study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Flavonoids; Humans; Inflammation; Knee; Male | 2019 |
Multiple physician visits after restricting the prescription of compresses/patches in a Japanese rural community: preliminary results.
Topics: Administration, Topical; Aged; Aged, 80 and over; Female; Humans; Male; Office Visits; Osteoarthriti | 2019 |
Topical Ginger Treatment With a Compress or Patch for Osteoarthritis Symptoms.
Topics: Administration, Topical; Aged; Female; Humans; Male; Middle Aged; New Zealand; Osteoarthritis; Pain; | 2014 |
Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study.
Topics: Age Factors; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Human | 2014 |
Supraclavicular nerve entrapment syndrome.
Topics: Analgesics; Antirheumatic Agents; Brachial Plexus; Clavicle; Humans; Lidocaine; Male; Middle Aged; N | 2012 |